Mayfair Advisory Group LLC Raises Stake in Moderna, Inc. (NASDAQ:MRNA)

Mayfair Advisory Group LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 6.0% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 2,164 shares of the company’s stock after buying an additional 122 shares during the period. Mayfair Advisory Group LLC’s holdings in Moderna were worth $231,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of MRNA. 180 Wealth Advisors LLC boosted its position in shares of Moderna by 4.8% in the first quarter. 180 Wealth Advisors LLC now owns 14,708 shares of the company’s stock worth $1,567,000 after buying an additional 675 shares during the period. Sound Income Strategies LLC lifted its position in Moderna by 41.3% during the 1st quarter. Sound Income Strategies LLC now owns 1,077 shares of the company’s stock worth $115,000 after acquiring an additional 315 shares in the last quarter. TB Alternative Assets Ltd. purchased a new position in Moderna in the 1st quarter worth approximately $6,383,000. Ballentine Partners LLC raised its stake in shares of Moderna by 125.4% during the first quarter. Ballentine Partners LLC now owns 4,747 shares of the company’s stock valued at $506,000 after purchasing an additional 2,641 shares during the period. Finally, Douglas Lane & Associates LLC lifted its position in shares of Moderna by 16.9% during the first quarter. Douglas Lane & Associates LLC now owns 393,039 shares of the company’s stock worth $41,882,000 after purchasing an additional 56,901 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the transaction, the director now owns 2,086,931 shares of the company’s stock, valued at approximately $212,199,144.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Shannon Thyme Klinger sold 5,178 shares of Moderna stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $148.09, for a total transaction of $766,810.02. Following the transaction, the insider now directly owns 15,947 shares of the company’s stock, valued at $2,361,591.23. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the completion of the sale, the director now directly owns 2,086,931 shares of the company’s stock, valued at $212,199,144.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 411,255 shares of company stock worth $56,118,931. 15.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

MRNA has been the topic of a number of recent analyst reports. Royal Bank of Canada boosted their price objective on shares of Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. William Blair restated a “market perform” rating on shares of Moderna in a report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $214.00 target price on shares of Moderna in a research note on Thursday. Finally, Canaccord Genuity Group lifted their price target on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $134.02.

Moderna Stock Performance

Shares of MRNA stock traded down $2.43 during trading hours on Friday, reaching $118.75. The stock had a trading volume of 3,976,313 shares, compared to its average volume of 3,869,466. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The firm has a 50-day simple moving average of $134.13 and a 200-day simple moving average of $112.19. The firm has a market capitalization of $45.51 billion, a PE ratio of -7.58 and a beta of 1.54. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. As a group, equities analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.